Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

14.67
+0.14000.96%
Volume:586.85K
Turnover:8.74M
Market Cap:944.08M
PE:-4.23
High:15.19
Open:14.76
Low:14.63
Close:14.53
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.59
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:2.93
PE(LYR):-3.94

Loading ...

Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)

TIPRANKS
·
Jun 11

BUZZ-Cullinan rises as early-stage data show remission in autoimmune disease drugs

Reuters
·
Jun 10

Cullinan Therapeutics releases Immunology Day presentation

Reuters
·
Jun 10

Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps

MT Newswires Live
·
Jun 10

Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data

TIPRANKS
·
Jun 10

Cullinan Therapeutics reports CLN-978, velinotamig data

TIPRANKS
·
Jun 10

Cullinan shares Phase 1 data showing CLN-978 induces remission in difficult-to-treat rheumatoid arthritis patients

Reuters
·
Jun 10

Cullinan: Sees Additional Multi-Dose Data for Cln-978 in Ra Next Quarter and in Sle in Q4, Additional Data for Velinotamig Before End of Year

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting Cd19 and Bcma in Autoimmune Diseases

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Inc: Cln-978 (Cd19 Tce) Eular Data Demonstrated Potential for Immune Reset, Including Remissions, in Both Sle and Ra

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

GlobeNewswire
·
Jun 10

Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data

TIPRANKS
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)

TIPRANKS
·
Jun 08

Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug

Dow Jones
·
Jun 08

Cullinan Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM) and Pfizer (PFE)

TIPRANKS
·
Jun 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM)

TIPRANKS
·
Jun 08

Cullinan Therapeutics presents clinical data for CLN-978

TIPRANKS
·
Jun 08

Cullinan Therapeutics Inc -Cln-978 Shows Favorable Safety Profile With Single Target Doses up to 30 ΜG as Well as Initial Multi-Dose Regimen

THOMSON REUTERS
·
Jun 06

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

GlobeNewswire
·
Jun 06